Roche collaboration for lead asset boosts Tempest

seekingalpha10-10

Shares of Tempest Therapeutics (NASDAQ:TPST) surged ~29% in the pre-market on Thursday after the company announced an agreement with Swiss pharma giant Roche (OTCQX:RHHBY) to further develop its lead ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474035714?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/483396687/image_483396687.jpg","is_english":true,"pubTime":"2024-10-10 19:51","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2474035714","market":"us","top_or_hot":-1,"title":"Roche collaboration for lead asset boosts Tempest","media":"seekingalpha","content":"<div>\n<p>Shares of Tempest Therapeutics (NASDAQ:TPST) surged ~29% in the pre-market on Thursday after the company announced an agreement with Swiss pharma giant Roche (OTCQX:RHHBY) to further develop its lead ...</p>\n\n<a href=\"https://seekingalpha.com/news/4157524-tempest-stock-gains-roche-collaboration\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche collaboration for lead asset boosts Tempest</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche collaboration for lead asset boosts Tempest\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 19:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4157524-tempest-stock-gains-roche-collaboration><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Tempest Therapeutics (NASDAQ:TPST) surged ~29% in the pre-market on Thursday after the company announced an agreement with Swiss pharma giant Roche (OTCQX:RHHBY) to further develop its lead ...</p>\n\n<a href=\"https://seekingalpha.com/news/4157524-tempest-stock-gains-roche-collaboration\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TPST","symbol_name":"Tempest Therapeutics Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/4157524-tempest-stock-gains-roche-collaboration","article_id":"2474035714","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/483396687/image_483396687.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474035714","pubTimestamp":1728561084,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Tempest Therapeutics  surged ~29% in the pre-market on Thursday after the company announced an agreement with Swiss pharma giant Roche  to further develop its lead asset amezalpat . According to the deal, Roche  will supply its anti-PD-L1 immunotherapy atezolizumab  to support a Phase 3 trial Tempest  expects to start in Q1 2025 targeting patients with hepatocellular carcinoma, a form of liver cancer.  The pivotal trial is designed to evaluate amezalpat in combination with the current standard of care, atezolizumab plus bevacizumab, as a first-line option for unresectable or metastatic hepatocellular carcinoma. “Based on the positive Phase 2 data, I believe this combination therapy holds the potential to significantly improve first-line liver cancer treatment, and we look forward to amezalpat moving into this pivotal Phase 3 study,” TPST CEO Stephen Brady remarked.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TPST":"Tempest Therapeutics Inc.","BK4139":"生物科技","BK4007":"制药","RHHBF":"Roche Holding Ltd","RHHBY":"罗氏控股","03165":"华夏欧优股对冲"},"translate_title":"罗氏在主导资产方面的合作推动了Tempest的发展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBF":0.9,"RHHBY":0.9,"TPST":0.9,"03165":0.6},"content_text":"Shares of Tempest Therapeutics (NASDAQ:TPST) surged ~29% in the pre-market on Thursday after the company announced an agreement with Swiss pharma giant Roche (OTCQX:RHHBY) to further develop its lead asset amezalpat (TPST-1120). According to the deal, Roche (OTCQX:RHHBF) will supply its anti-PD-L1 immunotherapy atezolizumab (Tecentriq) to support a Phase 3 trial Tempest (TPST) expects to start in Q1 2025 targeting patients with hepatocellular carcinoma, a form of liver cancer.  The pivotal trial is designed to evaluate amezalpat in combination with the current standard of care, atezolizumab plus bevacizumab, as a first-line option for unresectable or metastatic hepatocellular carcinoma. “Based on the positive Phase 2 data, I believe this combination therapy holds the potential to significantly improve first-line liver cancer treatment, and we look forward to amezalpat moving into this pivotal Phase 3 study,” TPST CEO Stephen Brady remarked.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474035714"}